Innoviva (INVA) Competitors $18.92 +0.10 (+0.53%) As of 10:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INVA vs. BCRX, LGND, FOLD, MNKD, CLDX, DVAX, NVAX, OPK, GERN, and RGLSShould you be buying Innoviva stock or one of its competitors? The main competitors of Innoviva include BioCryst Pharmaceuticals (BCRX), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), MannKind (MNKD), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry. Innoviva vs. BioCryst Pharmaceuticals Ligand Pharmaceuticals Amicus Therapeutics MannKind Celldex Therapeutics Dynavax Technologies Novavax OPKO Health Geron Regulus Therapeutics Innoviva (NASDAQ:INVA) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends. Do institutionals & insiders believe in INVA or BCRX? 99.1% of Innoviva shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 2.3% of Innoviva shares are held by company insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in INVA or BCRX? BioCryst Pharmaceuticals received 193 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 67.16% of users gave BioCryst Pharmaceuticals an outperform vote while only 57.52% of users gave Innoviva an outperform vote. CompanyUnderperformOutperformInnovivaOutperform Votes30657.52% Underperform Votes22642.48% BioCryst PharmaceuticalsOutperform Votes49967.16% Underperform Votes24432.84% Does the media refer more to INVA or BCRX? In the previous week, BioCryst Pharmaceuticals had 1 more articles in the media than Innoviva. MarketBeat recorded 11 mentions for BioCryst Pharmaceuticals and 10 mentions for Innoviva. Innoviva's average media sentiment score of 1.42 beat BioCryst Pharmaceuticals' score of 1.10 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend INVA or BCRX? Innoviva currently has a consensus target price of $55.00, suggesting a potential upside of 190.70%. BioCryst Pharmaceuticals has a consensus target price of $16.56, suggesting a potential upside of 59.28%. Given Innoviva's stronger consensus rating and higher possible upside, equities analysts plainly believe Innoviva is more favorable than BioCryst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innoviva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Which has more risk and volatility, INVA or BCRX? Innoviva has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Is INVA or BCRX more profitable? Innoviva has a net margin of 18.31% compared to BioCryst Pharmaceuticals' net margin of -30.01%. Innoviva's return on equity of 20.84% beat BioCryst Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Innoviva18.31% 20.84% 11.38% BioCryst Pharmaceuticals -30.01%N/A -24.06% Which has higher earnings and valuation, INVA or BCRX? Innoviva has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnoviva$369.84M3.21$179.72M-$1.01-18.73BioCryst Pharmaceuticals$503.49M4.32-$226.54M-$0.26-39.98 SummaryInnoviva and BioCryst Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Get Innoviva News Delivered to You Automatically Sign up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INVA vs. The Competition Export to ExcelMetricInnovivaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.18B$6.47B$5.31B$8.28BDividend YieldN/A2.64%5.20%4.10%P/E Ratio27.358.9026.7319.58Price / Sales3.21257.08387.44119.65Price / Cash5.1765.8538.2534.62Price / Book1.776.406.744.47Net Income$179.72M$143.98M$3.23B$248.22M7 Day Performance1.83%-0.09%-0.05%-1.32%1 Month Performance2.99%1.55%8.51%10.73%1 Year Performance19.82%-0.62%18.25%8.40% Innoviva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INVAInnoviva4.3358 of 5 stars$18.92+0.5%$55.00+190.7%+17.0%$1.18B$369.84M27.35100Positive NewsBCRXBioCryst Pharmaceuticals4.6177 of 5 stars$10.34+3.7%$16.56+60.1%+56.0%$2.16B$503.49M-16.95530Positive NewsAnalyst UpgradeLGNDLigand Pharmaceuticals4.3412 of 5 stars$106.38+1.8%$146.14+37.4%+16.1%$2.05B$181.49M42.3880Positive NewsFOLDAmicus Therapeutics3.9848 of 5 stars$6.21+3.8%$16.22+161.2%-35.6%$1.91B$543.14M-34.50480Positive NewsHigh Trading VolumeMNKDMannKind2.9214 of 5 stars$4.81+5.5%$10.00+107.9%-12.4%$1.46B$297.60M68.71400CLDXCelldex Therapeutics1.9657 of 5 stars$20.18+10.1%$53.90+167.1%-46.5%$1.34B$7.02M-7.85150Positive NewsDVAXDynavax Technologies4.1554 of 5 stars$9.85+4.7%$24.00+143.7%-17.3%$1.18B$294.62M54.72350High Trading VolumeNVAXNovavax3.7195 of 5 stars$6.34+6.2%$17.71+179.4%-53.6%$1.02B$682.16M-2.811,990OPKOPKO Health4.3183 of 5 stars$1.26+1.6%$2.75+118.3%-3.8%$999.25M$689.41M-6.634,200GERNGeron4.1295 of 5 stars$1.28+8.5%$5.06+295.5%-59.6%$815.26M$116.29M-4.0070Positive NewsGap DownRGLSRegulus Therapeutics1.2871 of 5 stars$7.87flat$8.50+8.0%+312.0%$521.33MN/A-7.3630 Related Companies and Tools Related Companies BioCryst Pharmaceuticals Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives MannKind Alternatives Celldex Therapeutics Alternatives Dynavax Technologies Alternatives Novavax Alternatives OPKO Health Alternatives Geron Alternatives Regulus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INVA) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innoviva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.